Title |
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131
|
---|---|
Published in |
Journal of Neuro-Oncology, June 2015
|
DOI | 10.1007/s11060-015-1845-7 |
Pubmed ID | |
Authors |
Michael A. Vogelbaum, Chen Hu, David M. Peereboom, David R. Macdonald, Caterina Giannini, John H. Suh, Robert B. Jenkins, Nadia N. Laack, David G. Brachman, Dennis C. Shrieve, Luis Souhami, Minesh P. Mehta |
Abstract |
We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma. Pre-RT temozolomide was given for up to 6 cycles. RT with concurrent temozolomide was administered to patients with less than a complete radiographic response. Forty eligible patients were entered and 32 completed protocol treatment. With a median follow-up time of 8.7 years (range 1.1-10.1), median progression-free survival (PFS) is 5.8 years (95 % CI 2.0, NR) and median overall survival (OS) has not been reached (5.9, NR). 1p/19q data are available in 37 cases; 23 tumors had codeletion while 14 tumors had no loss or loss of only 1p or 19q (non-codeleted). In codeleted patients, 9 patients have progressed and 4 have died; neither median PFS nor OS have been reached and two patients who received only pre-RT temozolomide and no RT have remained progression-free for over 7 years. 3-year PFS and 6-year OS are 78 % (95 % CI 61-95 %) and 83 % (95 % CI 67-98 %), respectively. Codeleted patients show a trend towards improved 6-year survival when compared to the codeleted procarbazine/CCNU/vincristrine (PCV) and RT cohort in RTOG 9402 (67 %, 95 % CI 55-79 %). For non-codeleted patients, median PFS and OS are 1.3 and 5.8 years, respectively. These updated results suggest that the regimen of dose intense, pre-RT temozolomide followed by concurrent RT/temozolomide has significant activity, particularly in patients with 1p/19q codeleted AOs and MAOs. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Unknown | 48 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 6 | 12% |
Researcher | 6 | 12% |
Student > Bachelor | 5 | 10% |
Student > Ph. D. Student | 5 | 10% |
Other | 4 | 8% |
Other | 11 | 22% |
Unknown | 12 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 53% |
Psychology | 3 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Nursing and Health Professions | 1 | 2% |
Other | 2 | 4% |
Unknown | 14 | 29% |